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Understanding the physiopathology of affective
disorders and their treatment relies on the availability
of experimental models that accuratelymimic aspects
of the disease. Here we describe a mouse model of
an anxiety/depressive-like state induced by chronic
corticosterone treatment. Furthermore, chronic anti-
depressant treatment reversed the behavioral dys-
functions and the inhibition of hippocampal neuro-
genesis induced by corticosterone treatment. In
corticosterone-treated mice where hippocampal
neurogenesis is abolished by X-irradiation, the effi-
cacy of fluoxetine is blocked in some, but not all,
behavioral paradigms, suggesting both neurogene-
sis-dependent and -independent mechanisms of
antidepressant action. Finally, we identified a number
of candidate genes, the expression of which is de-
creased by chronic corticosterone and normalized
by chronic fluoxetine treatment selectively in the
hypothalamus. Importantly, mice deficient in one
of these genes, b-arrestin 2, displayed a reduced
response to fluoxetine in multiple tasks, suggesting
that b-arrestin signaling is necessary for the antide-
pressant effects of fluoxetine.
INTRODUCTION
Depression and anxiety are distinct psychiatric disorders with
a high comorbidity. Selective serotonin reuptake inhibitors
(SSRIs) are the most commonly prescribed drugs for the treat-
ment of depression and several anxiety disorders. However,
the actions of SSRIs at the molecular and cellular level still
remain poorly understood. Furthermore, successful develop-ment of animal models displaying features of depression/anxiety
disorders that are responsive to treatment remains in its infancy.
Recently, compelling work has suggested that SSRIs exert their
behavioral activity in rodents through cellular and molecular
changes in the hippocampus as well as other brain structures
(Santarelli et al., 2003; Airan et al., 2007; Surget et al., 2008;
Wang et al., 2008; David et al., 2007).
The hypothalamo-pituitary-adrenal (HPA) axis, a crossroad
between central and peripheral pathways, is also known to
play a key role in the pathogenesis of mood disorders (de Kloet
et al., 2005). Similarities between features of depression/anxiety
and disorders associated with elevated glucocorticoid levels
have been reported (Sheline, 1996; Gould et al., 1998; McEwen,
1999; Airan et al., 2007; Grippo et al., 2005; Popa et al., 2008).
Based on these findings, long-term exposure to exogenous
corticosterone (4-pregnen-11b-DIOL-3 20-DIONE 21-hemisuc-
cinate) in rodents has been used to induce anxiety/depression-
like changes in behavior, neurochemistry, and brain morphology
(Ardayfio and Kim, 2006; Murray et al., 2008; Gourley et al.,
2008). Recent results demonstrated that behavioral deficits
and decreased cell proliferation in the dentate gyrus of adult
mice induced by elevation of glucocorticoid levels are reversed
by chronic monoaminergic antidepressant treatment (Murray
et al., 2008). In addition, in a chronic stress paradigm, the behav-
ioral effects of some, but not all, antidepressants are blocked by
the ablation of hippocampal neurogenesis (Surget et al., 2008).
In this study we model an anxiety/depressive-like state in mice
by studying the consequences of excess glucocorticoids in an
attempt to investigate both neurogenesis-dependent and -inde-
pendentmechanisms required for the functions of monoaminergic
antidepressants. To this end, we show that chronic treatment
with fluoxetine and imipramine in mice reverses the behavioral
dysfunction induced by long-term exposure to corticosterone in
the Open Field (OF) paradigm, Novelty Suppressed Feeding
(NSF) test, Forced Swim test (FST), and splash test of grooming
behavior.Neuron 62, 479–493, May 28, 2009 ª2009 Elsevier Inc. 479
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Neurogenesis and the Antidepressant ResponseChronic antidepressant treatment also stimulates the prolifer-
ation, differentiation, and survival of neural progenitors in the
dentate gyrus. Focal X-irradiation that ablates neurogenesis in
the hippocampus while leaving other brain areas intact (Santar-
elli et al., 2003; David et al., 2007), coupled with behavioral tests,
indicates that there are neurogenesis-dependent and -indepen-
dent mechanisms mediated by chronic fluoxetine in our model of
an anxiety/depression-like state.
The neurogenesis-independent mechanisms underlying anti-
depressant efficacy may be linked to changes in signaling in brain
areas other than the hippocampus, as we show that three genes
related to G protein receptor coupling, b-arrestin 1, b-arrestin 2,
and Gia2 proteins, have decreased expression in the hypothal-
amus that is reversed by fluoxetine. Genetic ablation of b-arrestin
2 blocked several effects of fluoxetine on behavior, suggesting
that b-arrestins are necessary for the anxiolytic/antidepressant
activity of this drug.
RESULTS
A complete statistical summary is included in Tables S2–S4,
available online.
Effects of a 3 Week Antidepressant Treatment
in a Stress-Related Model of Anxiety/Depression
Recently, multiple studies have confirmed that long-term expo-
sure to glucocorticoids induces anxiety and depressive-like
states in rodents (Stone and Lin, 2008; Gourley et al., 2008; Mur-
ray et al., 2008). Using a low dose of corticosterone (35 ug/ml/day
or 5 mg/kg/day), we found that C57BL/6Ntac and CD1 mice
treated for 4 weeks developed an anxiety-like phenotype in
both the OF and NSF test (Figure 1 and Figures S2 and S5, avail-
able online).
We first tested the effects of 3 week treatment with two distinct
antidepressants, a tricyclic (imipramine 40 mg/kg/day) and an
SSRI (fluoxetine 18 mg/kg/day), in our model of corticosterone-
induced anxiety/depression-like behavior in C57BL/6Ntac mice(see experimental design, Figure S1). In the OF, chronic exoge-
nous corticosterone had a marked effect on all anxiety parame-
ters, resulting in decreased time spent in the center (Figure 1A)
and decreased number of entries to the center (data not shown).
Interestingly, this anxiety phenotype was reversed by chronic
antidepressant treatment (two-way ANOVA, **p < 0.01, Figures
1A and S7, significant effects of pretreatment, treatment factors,
and sampling pretreatment x treatment interactions during the
OF sessions [**p < 0.01]). Regarding the total ambulatory
distance, chronic corticosterone treatment showed a nonsignifi-
cant trend that was abolished by chronic fluoxetine treatment
(Figure 1B). Since this trend may affect interpretation of results,
we also checked the ratio of total distance in center divided by
total distance (or percent path in the center). We found that corti-
costerone still induced an anxiety-like phenotype as it decreased
this measure (Figure S7B). Both fluoxetine and imipramine
significantly reversed this phenotype. These data suggest that
chronic corticosterone treatment can model an anxious-like
state that is responsive to treatment with distinct classes of
antidepressants.
In the NSF test, we found that chronic corticosterone treatment
led to a significant increase in latency to feed (Figure 1C). We then
explored whether antidepressants were able to reverse this
anxiety/depressive-like state observed in the NSF. Similar to the
OF, the change (+36%) in latency to feed induced by chronic corti-
costerone was reversed by chronic fluoxetine (18 mg/kg/day)
and imipramine (40 mg/kg/day) (Figure 1C, Kaplan-Meier survival
analysis, Mantel-Cox log-rank test, **p < 0.01, Figure S7C),
without affecting the home food consumption (Figure S7).
These data further suggest that chronic corticosterone models a
state of anxiety/depression that is responsive to antidepressant
treatment.
In the mouse FST, two-way ANOVA revealed that chronic corti-
costerone had no effect, while both fluoxetine and imipramine
treatment decreased the duration of mobility during the last
four minutes of the test (Figure 1D; significant treatment factor
effect [**p < 0.01]). The increase in mobility duration with bothFigure 1. Chronic Antidepressant Treatment following Corticosterone-Induced Behavioral Changes
(A and B) Effects of 3 weeks of antidepressant treatment (IMI: imipramine; FLX: fluoxetine), started after 4 weeks of corticosterone (35 ug/ml/day), on anxiety
behaviors in the Open Field test. Anxiety is measured as mean of the total time spent in the center in seconds (A). Locomotor activity is measured as total ambu-
latory distance traveled (B). Values plotted are mean ± SEM (n = 10–12 per group). **p < 0.01, #p < 0.05, ##p < 0.01, versus control group and corticosterone/
vehicle group, respectively.
(C) Effects of chronic antidepressant treatment on anxiety- and depression-like behaviors in the Novelty Suppressed Feeding paradigm after 7 weeks of corti-
costerone. Results are expressed as mean of latency to feed in seconds. Values plotted are mean ± SEM (n = 10–12 per group). **p < 0.01, ##p < 0.01, versus
control group and corticosterone/vehicle group, respectively.
(D) Effects of chronic antidepressant treatment in the mouse Forced Swim Test after 7 weeks of corticosterone. Results are expressed as mean of mobility
duration in seconds. Values plotted are mean ± SEM (n = 10–12 per group). **p < 0.01, ##p < 0.01, versus control group and corticosterone/vehicle group,
respectively.
(E) Effects of chronic antidepressant treatment on corticosterone-induced deterioration of the coat state. Results are expressed as the total resulting from the
sum of the score of five different body parts. Values plotted are mean ± SEM (n = 10–12 per group). **p < 0.01, #p < 0.05, versus vehicle group and corticosterone/
vehicle group, respectively.
(F) Effects of chronic antidepressant treatment on corticosterone-induced anxiety- and depression-related behaviors in the splash test. Results are expressed as
mean frequency of grooming after receiving a 10% sucrose solution on the snout. Values plotted are mean ± SEM (n = 10–12 per group). **p < 0.01, ##p < 0.01,
versus control group and corticosterone/vehicle group, respectively.
(G) The effects of 3 weeks of antidepressant treatment (reboxetine 20 mg/kg/day; fluoxetine, 18 mg/kg/day), started after 4 weeks of corticosterone (35 ug/ml/day),
on anxiety behaviors in the elevated plus maze. Anxiety is expressed as mean total entries in the open arms. Values plotted are mean ± SEM (n = 12–15 per group).
**p < 0.01, versus corticosterone/vehicle group.
(H) Effects of chronic antidepressant treatment on corticosterone-induced behavior in the Tail Suspension Test. Results are expressed as mean of mobility duration
in seconds. Values plotted are mean ± SEM (n = 12–15 per group). *p < 0.05, **p < 0.01, versus corticosterone/vehicle group.Neuron 62, 479–493, May 28, 2009 ª2009 Elsevier Inc. 481
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Neurogenesis and the Antidepressant ResponseFigure 2. Fluoxetine Stimulates Cell Proliferation, Survival, and Dendritic Maturation of Young Neurons in the Dentate Gyrus of the Adult
Hippocampus
(A) BrdU (150 mg/kg) was given 2 hr before sacrifice to examine the effects of 7 weeks of corticosterone (35 ug/ml/day) ± fluoxetine (FLX, 18 mg/kg/day) during the
last 3 weeks. Data are the mean ± SEM of the BrdU-positive cell counts from 3–4 animals per treatment group for the subgranular zone and adjacent zone, defined
as a two-cell-body-wide zone along the hilar border (40x magnification). *p < 0.05, ##p < 0.01, xp < 0.05, versus vehicle group, corticosterone/vehicle group, and
fluoxetine/vehicle group, respectively.482 Neuron 62, 479–493, May 28, 2009 ª2009 Elsevier Inc.
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Neurogenesis and the Antidepressant Responseantidepressants was observed in corticosterone-treated (from
12.2 ± 2.3 s in corticosterone group to 31.7 ± 5.1 s and 20.3 ±
3.3 s in corticosterone/fluoxetine and corticosterone/imipramine
group, respectively) and non-corticosterone-treated animals
(from 12.2 ± 2.4 s in vehicle [hydroxypropyl-b-cyclodextrin, or
b-CD] to 30.3 ± 5.3 s and 20.7 ± 3.6 s in fluoxetine and imipramine
group, respectively).
We next assessed the coat state of the animals. This measure
has been described as a reliable and well-validated index of
a depressed-like state (Griebel et al., 2002; Santarelli et al.,
2003). Long-term glucocorticoid exposure, similar to chronic
stress (Surget et al., 2008), induced physical changes including
deterioration of coat state (Figures 1E and S3A) and altered
body weight (Figure S3B). Importantly, a 3 week fluoxetine
regimen significantly reversed the deterioration of the coat state
(Figure 1E) induced by chronic corticosterone (from 2.23 ± 0.09
to 1.80 ± 0.08) (two-way ANOVA with significant effect of
pretreatment, treatment factors, and sampling pretreatment x
treatment interactions [**p < 0.01]).
We then investigated whether the deterioration of the coat
state was linked to changes in grooming behavior (Figure 1F).
We observed that after squirting a 10% sucrose solution on the
mouse’s snout, the decreased grooming frequency (55%, Fig-
ure 1F) induced by corticosterone treatment was reversed with
3 weeks of fluoxetine treatment (18 mg/kg/day) (from 3.3 ± 0.5 to
9 ± 1) [two-way ANOVA with significant treatment and pretreat-
ment factors [*p < 0.05 and **p < 0.01]). Taken together, these
results suggest through multiple behavioral readouts that chronic
antidepressant treatment is effective in reversing an anxiety/
depression-like phenotype induced by excess glucocorticoids.
To further validate our model, we next tested the effects of
fluoxetine and a norepinephrine reuptake inhibitor (NRI) (reboxe-
tine 20 mg/kg/day) in chronic corticosterone-treated animals
using two additional behavioral measures. In the elevated plus
maze, a test associated with anxiety, we found that chronic
fluoxetine increased entries into the open arms, while mice
treated with reboxetine displayed a strong trend in this measure
(Figure 1G; one-way ANOVA, significant effect of treatment [**p <
0.01]). Furthermore, in the Tail Suspension Test (TST), a test of
response to antidepressants, both chronic fluoxetine and rebox-
etine significantly increased mobility (Figure 1H; one-way
ANOVA, significant effect of treatment [**p < 0.01, *p < 0.05]).
We also looked at the effects of chronic corticosterone
treatment on the response of the HPA axis to an acute stress.
The increase of corticosterone elicited by stress in the control
mice was markedly attenuated in corticosterone-treated
animals (Figure S3E) (two-way ANOVA with significant effect ofpretreatment, treatment factor, and pretreatment x treatment
interaction for corticosterone levels [**p < 0.01]). Fluoxetine
and imipramine had no effect on stress-induced corticosterone
levels, both in baseline conditions and after chronic corticoste-
rone treatment.
Chronic Fluoxetine Treatment after Long-Term
Corticosterone Exposure Affects All Stages
of Adult Hippocampal Neurogenesis
To investigate the potential cellular mechanisms underlying the
behavioral effects of fluoxetine, we next evaluated changes in
adult hippocampal neurogenesis hypothesized to be relevant
for antidepressant action (Santarelli et al., 2003; Airan et al.,
2007).
In agreement with previous observations (Murray et al., 2008;
Qiu et al., 2007), chronic corticosterone exposure mimicked the
effect of chronic stress on cell proliferation (Surget et al., 2008),
decreasing the number of BrdU-positive cells in the dentate
gyrus of the adult mouse hippocampus (25%) (Figure 2A)
(two-way ANOVA with significant effect of treatment factor and
sampling pretreatment x treatment interactions [**p < 0.01]).
This change in cell proliferation induced by corticosterone
was completely reversed by 3 weeks of fluoxetine treatment
(18 mg/kg/day). Interestingly, fluoxetine induced a very large
and significant effect on proliferation in corticosterone-treated
mice, but not in non-corticosterone-treated animals (BrdU-posi-
tive cells: from 1335 ± 98.3 in corticosterone-treated animals to
3570 ± 733.1 in corticosterone/fluoxetine group).
Although chronic corticosterone treatment alone altered cell
proliferation, it did not affect the survival of newborn neurons
(Figure 2B) or the number of dendrites and dendritic morphology
in doublecortin-positive cells (Figures 2C–2F, 2H, and 2I). A
similar lack of effect on cell survival has been observed after
chronic mild stress in rats (Heine et al., 2004; Airan et al.,
2007). Furthermore, as we previously described, chronic fluoxe-
tine increased the number of doublecortin-positive cells with
tertiary dendrites and the maturation index in control animals
(Figures 2H and 2I) (Wang et al., 2008). However, the effect of
fluoxetine is more pronounced in the presence of corticosterone
when assessing survival (Figure 2B, two-way ANOVA with signif-
icant effect of treatment factor, *p < 0.05) as well as when count-
ing the number of doublecortin-positive cells and assessing their
dendritic morphology [Figure 2G; significant effect of treatment
factor [**p < 0.01]; Figure 2H; two-way ANOVA with significant
effect of treatment factor [**p < 0.01]). These results indicate
that antidepressants stimulate all stages of adult neurogenesis
in an animal model of an anxiety/depression-like phenotype.(B) BrdU was given twice a day for 3 days prior to drug treatment to examine the effects of 7 weeks of corticosterone ± fluoxetine during the last 3 weeks. Data are
the mean ± SEM of the BrdU-positive cells from 5–6 animals per treatment group. *p < 0.05, #p < 0.05, versus vehicle group and corticosterone/vehicle group,
respectively.
(C–F) Images of doublecortin staining following corticosterone for 7 weeks ± chronic fluoxetine treatment for the last 3 weeks. 10x magnification and 20x for the
inset. Left panels (C and E) are vehicle and right panels (D and F) are fluoxetine-treated groups.
(G) Effects of fluoxetine treatment on total number of doublecortin-positive cells (mean ± SEM; n = 4 per group) were measured after 7 weeks of corticosterone.
**p < 0.01, #p < 0.05, xp < 0.05, versus vehicle group, corticosterone/vehicle group, and fluoxetine group, respectively.
(H and I) Doublecortin-positive cells were categorized as to whether they exhibited tertiary dendrites. Effects of fluoxetine treatment on the doublecortin-positive
cells with tertiary dendrites (H) and maturation (I) of newborn granule cells were measured after 7 weeks of corticosterone. Values are mean ± SEM (n = 5 per
group). **p < 0.01, ##p < 0.01, xp < 0.05, versus vehicle group, corticosterone/vehicle group, and fluoxetine/vehicle group, respectively.Neuron 62, 479–493, May 28, 2009 ª2009 Elsevier Inc. 483
Neuron
Neurogenesis and the Antidepressant Response484 Neuron 62, 479–493, May 28, 2009 ª2009 Elsevier Inc.
Neuron
Neurogenesis and the Antidepressant ResponseThe Behavioral Effects of Fluoxetine in the Chronic
Corticosterone Model Are Mediated by Both
Neurogenesis-Dependent and Neurogenesis-
Independent Mechanisms
To assess whether adult neurogenesis is required for the antide-
pressant-mediated reversal of chronic corticosterone treatment
in several behavioral tasks, we next submitted animals to focal
hippocampal X-irradiation prior to a chronic corticosterone
regimen alone or in combination with fluoxetine (see timeline,
Figure S1).
In the OF paradigm, the complete loss of hippocampal neuro-
genesis did not impact the anxiety/depression-like effects of
chronic corticosterone. Moreover, the efficacy of fluoxetine was
not modified in irradiated mice for all the OF parameters tested
(Figures 3A–3D). Thus, the total decrease in the time spent in
the center (sham: 144.7 ± 16.2 s; X-ray: 143.2 ± 18.4 s in cortico-
sterone-treated animals), the total number of entries (sham: 285
± 45.1; X-ray: 275.2 ± 40.1 in corticosterone-treated animals),
and the ratio of center/total distance traveled (sham: 17.9% ±
4.4%; X-ray: 13.2% ± 3.2% in corticosterone-treated animals)
for all sessions after 7 weeks of corticosterone treatment were
reversed by chronic fluoxetine treatment regardless of whether
the mice were exposed to X-irradiation (Figures 3A–3D; two-
way ANOVA with significant treatment factor [*p < 0.05]).
In contrast, the effects of fluoxetine to reverse the anxiety/
depressive-like state induced by chronic corticosterone in the
NSF paradigm was completely abolished with hippocampal irra-
dation (from 371.3 ± 50.29 s in sham corticosterone/fluoxetine
group to 546.2 ± 36.5 s in irradiated corticosterone/fluoxetine
group) (Figures 3E and 3G; two-way ANOVA with significant inter-
action between irradiation and treatment [**p < 0.01]), suggesting
a dependence on adult hippocampal neurogenesis. Home cage
food consumption was not affected by fluoxetine or irradiation
(Figure 3F). In the mouse FST, the fluoxetine-induced decrease
in immobility duration in corticosterone-treated animals was not
affected by focal irradiation (Figure 3H).
Taken together, these results demonstrate that hippocampal
neurogenesis is required for the behavioral activity of fluoxetine
in the NSF test but not in the OF and FST, suggesting distinct
underlying mechanisms. Interestingly, this report indicates that
fluoxetine mediates its effects through distinct neurogenesis-
dependent and -independent mechanisms. A recent report has
suggested that antidepressants utilize both mechanisms, but
fluoxetine was suggested to be neurogenesis dependent while
distinct compounds that are V1B and corticotropin-releasingfactor type 1 (CRF1) antagonists were suggested to be neuro-
genesis-independent (Surget et al., 2008).
Chronic Fluoxetine Treatment Restored Normal Levels
of b-arrestin 1 and 2 and Gia2 mRNA in the
Hypothalamus, but Not in the Amygdala and the
Hippocampus, of Corticosterone-Treated Animals
We next wanted to further explore the distinct neurogenesis-
dependent and -independent mechanisms responsible for the
anxiolytic/antidepressant-like activity of fluoxetine. To this end,
we used a candidate-based approach to assess whether there
were changes in the expression of genes previously linked to
mood disorders (Avissar et al., 2004; Schreiber and Avissar,
2007; Perlis et al., 2007; de Kloet et al., 2005) in different brain
regions. Among a panel of more than 20 genes involved in
mood disorders, we only found 3 that were changed in our corti-
costerone model.
Long-term exposure to corticosterone (35 ug/ml/day) signifi-
cantly decreased b-arrestin 1 expression in the hypothalamus
and there was a similar trend in the amygdala (Figures 4A and
4D), but exposure did not affect expression in the hippocampus
(Figure 4G) (one-way ANOVA for gene expression in the hypothal-
amus [**p < 0.01]). Expression of Gia2 is also significantly
decreased with chronic corticosterone treatment in the hypotha-
lamus and the amygdala (Figures 4C and 4F) (one-way ANOVA for
gene expression in the hypothalamus and the amygdala [**p <
0.01]). Interestingly, the decrease of b-arrestin 1 (Figure 4A) and
Gia2 (Figure 4C) gene expression after 7 weeks of corticosterone
treatment was totally reversed by chronic fluoxetine treatment
in the hypothalamus, but not in the amygdala and the hippo-
campus (Figures 4D, 4F, 4G, and 4I) (one-way ANOVA for gene
expression in the hypothalamus [**p < 0.01]). We also found that
with b-arrestin 2 expression, a trend of decreased expression
(16%) was reversed with fluoxetine treatment in the hypothal-
amus, but not in the amygdala (Figures 4B, 4E, and 4H) (cortico-
sterone/vehicle group versus corticosterone/fluoxetine group in
the hypothalamus [p < 0.05]). Interestingly, in the hippocampus,
fluoxetine had an opposite effect onb-arrestin2 levels (Figure 4H).
From these three genes, we were particularly interested in
b-arrestin 2 because the gene expression profile was affected
differentially in the hippocampus and hypothalamus, which may
indicate an involvement in neurogenesis-dependent and -inde-
pendent effects of fluoxetine. Interestingly, b-arrestin 2 has
been implicated in pathways associated with responsiveness to
the mood stabilizer lithium (Beaulieu et al., 2008). There is alsoFigure 3. Neurogenesis-Dependent and -Independent Effects of Chronic Fluoxetine on Corticosterone-Induced Behavioral Changes
(A–D) The effects of fluoxetine (FLX, 18 mg/kg/day) treatment after focal X-irradiation of the mouse hippocampus on corticosterone (35 ug/ml/day) -induced
anxiety-like behaviors in the Open Field test. Anxiety is expressed as mean total time spent in seconds for each 5 min period (A) and for the entire session
(B), and also as the mean total of the number of entries (C). Locomotor activity is reported as percentage ambulatory distance in the center over total ambulatory
distance traveled (D). Values are mean ± SEM (n = 10–12 per group). *p < 0.05, **p < 0.01, #p < 0.05, versus control group and corticosterone/vehicle group,
respectively.
(E–G) Effects of fluoxetine treatment after focal X-irradiation on corticosterone-induced anxiety- and depression-related behaviors in the Novelty Suppressed
Feeding paradigm. Results are mean of latency to feed in seconds (E) or cumulative survival of animals that have not eaten over 10 min (G). Feeding drive
was assessed by returning the animals to their home cages and measuring food consumed over a period of 5 min (mg/g of mouse) (F). Values are mean ±
SEM (n = 10–12 per group). **p < 0.01 versus sham corticosterone/vehicle group.
(H) Effects of 3 weeks of fluoxetine treatment in 7 weeks corticosterone-treated animals after X-irradiation on behavior in the Forced Swim Test. Results are mean
of mobility duration in seconds. Values are mean ± SEM (n = 10–12 per group). **p < 0.01 versus control group.Neuron 62, 479–493, May 28, 2009 ª2009 Elsevier Inc. 485
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Neurogenesis and the Antidepressant ResponseFigure 4. Effects of Chronic Fluoxetine Treatment on Corticosterone-Induced Changes in b-arrestin 1, b-arrestin 2, and Gia2 Gene Expres-
sion in Mouse Hypothalamus, Amygdala, and Hippocampus
(A–C) Effects of fluoxetine (FLX, 18 mg/kg/day) treatment in corticosterone (35 ug/ml/day) -treated animals on the mean b-arrestin 1, b-arrestin 2, and Gia2 gene
expression (in percent normalized to cyclophilin and GAPDH gene expression) ± SEM (n = 10–12 per group) in the mouse hypothalamus. *p < 0.05, #p < 0.05,
versus control group and corticosterone/vehicle group, respectively.
(D–F) Same as above, performed for the mouse amygdala. *p < 0.05 versus control group.
(G–I) Same as above, performed for the mouse hippocampus. *p < 0.05 versus control group.evidence in humans implicating b-arrestins in depression and in
response to stress, and that these changes are reversible by anti-
depressant treatment (Dwivedi et al., 2002; Avissar et al., 2004).
b-arrestin 2 Is Necessary for the Anxiolytic/
Antidepressant Effects of Chronic Fluoxetine
We next proceeded to investigate the contribution of b-arrestin
2 to the behavioral effects of a 3 week treatment with fluoxetine486 Neuron 62, 479–493, May 28, 2009 ª2009 Elsevier Inc.(18 mg/kg/day). We started with the OF, where we found that
b-arrestin-2-deficient mice (mixed background 129/Sv x C57BL/
6J) in the control group display an anxious-like phenotype evi-
denced by a decrease in the amount of the time spent in the
center (Figure 5A) as well as a decreased number of entries into
the center relative to those of the untreated wild-type mice
(data not shown). Similar to a previous report (Beaulieu et al.,
2008), and like the corticosterone-treated C57BL/6Ntac mice,
Neuron
Neurogenesis and the Antidepressant Responsewe found a nonsignificant trend toward decreased ambulatory
activity in the b-arrestin-2-deficient mice. We therefore checked
the percent path in the center of the OF for these mice, and using
this normalized data found that the b-arrestin 2 mice were indeed
more anxious-like than their wild-type littermates (Figure S7F).
Chronic fluoxetine treatment had an effect on all anxiety
parameters in wild-type animals, resulting in a trend toward
increased time spent in the center (Figure 5A) and total number
of entries in the center (data not shown). Interestingly, planned
comparisons unveiled that this effect of fluoxetine treatment
is abolished in b-arrestin 2 knockout mice (two-way ANOVA
[**p < 0.01], Figure 5A, significant effects of pretreatment [**p <
0.01]). This absence of effects of fluoxetine in b-arrestin 2
knockout mice is also observed with the total number of entries
in the center (data not shown) and the total ambulatory distance
(Figure 5B, significant effect of pretreatment [**p < 0.01]). There-
fore, similar to the chronic corticosterone model, b-arrestin 2
knockout mice display an anxiety phenotype in the OF. However,
unlike the chronic corticosterone-treated mice, b-arrestin 2
knockout mice do not respond to fluoxetine treatment in the OF.
We next tested the b-arrestin-2-deficient mice in the Light-
Dark test, a behavioral paradigm also associated with anxiety.
Unlike in the OF, vehicle-treated b-arrestin 2 knockout mice
did not display an anxious-like phenotype as assessed by entries
in the light (Figure 5C). This is similar to a previous report,
wherein the b-arrestin 2 knockout mice did not display a pheno-
type in latency to cross using this test (Beaulieu et al., 2008).
However, we found a trend for fluoxetine to increase entries
into the light from control mice that was absent in the b-arrestin
2 knockout mice. Planned comparisons unveiled that the two
groups of mice were indeed responding differently to fluoxetine
(Figure 5C, two-way ANOVA, significant interaction pretreat-
ment x treatment [p = 0.04]). Importantly, there was no significant
difference observed in ambulatory distance in the dark among
any of the groups (Figure 5D, two-way ANOVA, no effect for
pretreatment or treatment). These data further demonstrate a
behavioral measure in which b-arrestin 2 knockout mice are
not responsive to fluoxetine.
We next tested the effects of fluoxetine in b-arrestin 2
knockout mice using the NSF paradigm. Importantly, untreated
b-arrestin 2 knockout mice display an anxious/depressive
phenotype evidenced by an increased latency to feed relative
to that of the untreated wild-type mice. Furthermore, while in
wild-type mice fluoxetine significantly decreased the latency to
feed in the novel environment, fluoxetine had no effect in mutant
mice (Figures 5E and S7G: Kaplan-Meier survival analysis,
Mantel-Cox log-rank test [**p < 0.01]). Food consumption in
the home cage was not altered (Figure 5F; two-way ANOVA
[p > 0.4]). Taken together, these data indicate that b-arrestin 2
is required for the behavioral effects of fluoxetine in the OF,
Light-Dark, and NSF tests.
To further understand the effects of fluoxetine in b-arrestin 2
knockout mice, we assessed behavior in the FST. Interestingly,
we found that b-arrestin 2 knockout mice treated with fluoxetine
behaved similarly to wild-type mice in that they displayed an
increase in mobility relative to the control group. Therefore, in
contrast to the OF, Light/Dark, and NSF results, b-arrestin 2 is
not necessary for the behavioral effects of chronic fluoxetine inthe mouse FST (two-way ANOVA, Figure 5G, significant effects
of treatment [**p < 0.01]).
Finally, we tested whether fluoxetine was effective in b-arrestin
2 knockout mice using the sucrose splash test of grooming.
While fluoxetine significantly increased grooming in control litter-
mates, b-arrestin 2 knockout mice did not respond (Figure 5H).
Gene Expression Profiles in b-arrestin-2-Deficient Mice
Indicate a Lack of Response to Fluoxetine
We next assessed gene expression profiles in b-arrestin 2
knockout mice and wild-type littermates treated with vehicle or
fluoxetine. We did not detect significant differences in b-arrestin
1 levels, suggesting that there is not compensation among the
arrestin proteins in the areas that we studied (hypothalamus,
amygdala, hippocampus) (Figures S8A, S8F, and S8K). Interest-
ingly, we did find that fluoxetine increased CREB1 levels in the
hippocampus in wild-type mice, but not in b-arrestin 2 knockouts
(Figure S8M). Likewise, fluoxetine increased Erk-1 levels in the
hypothalamus of wild-type mice, but not b-arrestin 2 knockouts
(Figure S8E). Taken together, these data suggest a differential
response to fluoxetine in the b-arrestin-2-deficient mice.
DISCUSSION
Our data indicate that the behavioral activity of antidepres-
sants such as fluoxetine requires both neurogenesis-dependent
and -independent mechanisms. We also provide evidence that
some of the effects of fluoxetine are mediated by a b-arrestin
signaling pathway.
Elevation of Glucocorticoids Levels Induces an Anxiety/
Depressive-like State in Mice that Is Reversed by
Chronic Antidepressants
Enhanced activity of the HPA axis involving elevated glucocorti-
coid levels is considered a key neurobiological alteration in major
depression (for review, see Antonijevic, 2006). In depressed
patients, many studies have shown that successful antidepres-
sant therapies are associated with normalization of impairments
in the HPA axis negative feedback (Greden et al., 1983; Linkowski
et al., 1987; Heuser et al., 1996; Holsboer-Trachsler et al., 1991).
This elevation of glucocorticoid levels in human has been
modeled in rodent to reproduce an anxiety and depressive-like
state (Ardayfio and Kim, 2006; Murray et al., 2008; Zhao et al.,
2008; Gourley et al., 2008). Our model of elevated glucocorto-
coids was able to blunt the response of the HPA axis as shown
by the markedly attenuated stress-induced corticosterone
levels observed in these mice (Figure S3E). This is probably a
consequence of the negative feedback exerted by corticosterone
on the HPA axis. Consistent with previous findings, our results
demonstrate that an elevation of glucocorticoid levels is sufficient
to induce anxiety in C57BL/6Ntac and CD1 mice as measured
by the decrease in center measures in the OF paradigm as well
as the increase in latency to feed in the NSF (Figures 1, S2, and
S5). A depressive-like state in the C57BL/6J corticosterone-
treated animals was also observed as measured by a deteriora-
tion of the coat state, a decreased grooming behavior, and a
flattened circadian rhythm with reduction in home cage activity
(Figures 1 and S4). These symptoms are similar to those elicitedNeuron 62, 479–493, May 28, 2009 ª2009 Elsevier Inc. 487
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depressed patients with elevated cortisol display anhedonia,
cognitive dysfunctions/distortions, and personal neglect (Morgan
et al., 2005). Therefore, chronic corticosterone treatment appears
to model an anxious and depressed-like state in mice.
When using the C57BL/6Ntac mice, in marked contrast to the
OF and NSF, the FST was the only behavioral model in which
antidepressants exerted effects in untreated non-anxious/
depressed mice. The absence of antidepressant effect in both
the NSF and OF suggests that different neurobiological mecha-
nisms are recruited by antidepressants when animals are exam-
ined in pathological conditions rather than standard home cage
conditions. Therefore, when pretreated with corticosterone,
mice that are normally nonresponsive to fluoxetine are rendered
responsive. Interestingly, when a more anxious strain is used,
such as the 129SvEv mice, it is possible to detect effects of
chronic antidepressants in standard home cage conditions (San-
tarelli et al., 2003). This is also evident in the b-arrestin 2 mice,
which are on a mixed background of C57BL/6J x 129SvEv and
are responsive to fluoxetine in standard home cage conditions
(Figure 5).
Importantly, we found high levels of mobility during the first
2 min of the FST in all groups. Therefore, we only assessed the
last 4 min of the 6 min test for our analysis. It is believed that
this is the critical time to detect potential effects of antidepres-
sants (Porsolt et al., 1977).
It is also noteworthy that neither fluoxetine nor imipramine
restored normal levels of corticosterone after an acute stressor,
which suggests that their mechanism of action may be indepen-
dent of the HPA axis.
Enhanced Effects of Fluoxetine Treatment on
Neurogenesis in Corticosterone-Treated Mice
Glucocorticoids and antidepressants have been shown to modu-
late adult neurogenesis in opposite directions, and hippocampal
neurogenesis is required for some of the effects of antidepres-
sants (Gould et al., 1992; McEwen, 1999; Duman et al., 2000;
Malberg et al., 2000; McEwen and Magarinos, 2001; Santarelli
et al., 2003; Airan et al., 2007; Surget et al., 2008; Murray et al.,
2008; Conrad et al., 2007). Since we previously demonstrated
that antidepressants increase all stages of neurogenesis, in-
cluding proliferation, maturation, and survival in normal mice,
we sought to understand the effects of fluoxetine on neurogene-
sis in mice that were in an anxious and depressed-like state.In agreement with previous findings (Murray et al., 2008), a
reduction in the proliferation of progenitor cells after chronic corti-
costerone treatment was observed (Figure 2), demonstrating
a role for glucocorticoids in the regulation of the proliferation
stage of the neurogenic process. Indeed, it had been reported
that ablation of the adrenal glands abolishes stress-induced
decreases in cell proliferation (Tanapat et al., 2001). Interestingly,
the effects of corticosterone on neurogenesis are limited to the
proliferation stage and not the survival or maturation of newborn
neurons. Similar results were observed in rat (Heine et al., 2004),
and it has been proposed that a decrease in apoptosis counter-
acts the reduction in neurogenesis elicited by stress and explains
the absence of change in number of newborn neurons after
chronic stress.
Surprisingly, chronic fluoxetine treatment did not affect hippo-
campal cell proliferation in non-corticosterone-treated C57BL/
6Ntac mice. Strain differences in hippocampal adult proliferation
have been reported (Schauwecker, 2006; Navailles et al., 2008)
and C57BL/6 strain exhibits one of the highest numbers of proli-
ferating cells within the subgranular zone, as compared to those
of other strains of mice.
Interestingly, the effects of fluoxetine on all stages of neuro-
genesis (proliferation, differentiation, and survival) were more
pronounced in corticosterone-treated mice than in controls. It
is possible that our model of corticosterone-induced stress
may increase the dynamic range in which fluoxetine exerts
effects on different stages of neurogenesis. These enhanced
effects may be due to changes in the serotonin system elicited
by chronic stress. In fact we and others have shown that chronic
stress results in a desensitization of 5-HT1A autoreceptors
(Hensler et al., 2007; data not shown), which is likely to result in
an increase in serotonin release and therefore, possibly, a
stronger effect of fluoxetine. There is also an interesting parallel
between these enhanced effects of fluoxetine on neurogenesis
and the fact that fluoxetine is more active behaviorally in the corti-
costerone-treated mice.
Neurogenesis-Dependent and -Independent
Mechanisms
We had shown earlier that some of the effects of antidepressants
in the NSF test require hippocampal neurogenesis (Santarelli
et al., 2003). Therefore, we hypothesized that the effect of fluox-
etine on the anxiogenic/depressive-like state in corticosterone-
treated mice may also require neurogenesis. Indeed, in theFigure 5. The Role of b-arrestin 2 in Mediating the Behavioral Effects of Chronic Fluoxetine
(A and B) Effects of 4 weeks of fluoxetine treatment (18 mg/kg/day) in b-arrestin 2 knockout mice (bArr2 KO) and littermates on anxiety behaviors in the Open Field.
Anxiety is expressed as mean time in the center (A). Locomotor activity is reported as ambulatory distance traveled for the entire session (B). Values are mean ±
SEM (n = 15–18 per group). xp < 0.05 versus fluoxetine-treated wild-type mice.
(C and D) Effects of chronic fluoxetine in b-arrestin 2 knockout mice and littermates in the Light-Dark paradigm. Results are mean total entries into the light (C).
Locomotor activity is reported as ambulatory distance traveled in the dark (D). Values plotted are mean ± SEM (n = 9–10 per group). xp < 0.05 versus fluoxetine-
treated wild-type mice.
(E and F) Effects of chronic fluoxetine in b-arrestin 2 knockout mice and littermates in Novelty Suppressed Feeding. Results are mean of latency to feed in seconds
(E). Feeding drive was assessed by returning the animals to their home cages after the test and measuring food consumed over 5 min (mg/g of mouse) (F). Values
are mean ± SEM (n = 15–18 per group). *p < 0.05 versus control group and fluoxetine-treated wild-type mice, respectively.
(G) Effects of chronic fluoxetine in b-arrestin 2 knockout mice and littermates in the Forced Swim Test. Results are mean of mobility duration in seconds. Values
are mean ± SEM (n = 15–18 per group). *p < 0.05, #p < 0.05, versus vehicle wild-type or b-arrestin 2 knockout animals, respectively.
(H) Effects of chronic fluoxetine in the splash test. Results are mean frequency of grooming after receiving a squirt of 10% sucrose solution on the snout. Values
are mean ± SEM (n = 9–10 per group). *p < 0.05, xxp < 0.01, versus vehicle wild-type group or fluoxetine-treated wild-type, respectively.Neuron 62, 479–493, May 28, 2009 ª2009 Elsevier Inc. 489
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Neurogenesis and the Antidepressant ResponseTable 1. Behavioral Effects of a Chronic Fluoxetine Treatment in the Chronic Corticosterone Paradigm and in the b-arrestin 2 KOMice
Open
Field Light-Dark
Elevated
Plus Maze
Novelty
Suppressed
Feeding
Splash
Test
Forced
Swim Test
Tail
Suspension
Test
time in
the center
entries into
the light
time in
open arms
latency
to feed
grooming
frequency
mobility
duration
mobility
duration
Chronic
corticosterone
paradigm
vehiclea Y not tested not tested [ Y 0 not tested
chronic fluoxetineb [ not tested [ Y [ [ [
b-arrestin
2 KO mice
vehiclec Y 0 not tested [ 0 0 [
chronic fluoxetined 0 0 not tested 0 0 [ 0
Summary of effects seen in multiple behavioral tests throughout the study. Y, decrease parameter; [, increase parameter; 0, no effect.
a Versus vehicle-treated group.
b Versus chronic corticosterone-treated group.
c Versus vehicle-treated wild-type littermate.
d Versus vehicle-treated b-arrestin KO mice.corticosterone model, the effects of fluoxetine in the NSF test
were blocked by X-irradiation. However, in the same animals,
in the OF and the FST, ablation of hippocampal neurogenesis
did not modify the anxiolytic/antidepressant-like activity of fluox-
etine (Figure 4). These behavioral effects are therefore likely to
recruit different pathways. To our knowledge, this is the first
study, using a model of anxiety/depression in mice, showing
that both neurogenesis-dependent and -independent mecha-
nisms are necessary for the effects of fluoxetine. Overall, these
studies suggest that hippocampal neurogenesis plays an impor-
tant role in the behavioral effects of fluoxetine. However, there is
accumulating evidence that other brain regions including amyg-
dala, nucleus accumbens, or cingulate cortex are also involved
in antidepressant-like activity. It is also possible that adult neuro-
genesis outside of the hippocampus may play a role in the
effects of fluoxetine (Kokoeva et al., 2005, 2007).
To explore the mechanism underlying the neurogenesis-inde-
pendent effects of fluoxetine, we analyzed gene expression
profiles in the hypothalamus, amygdale, and hippocampus, three
brain structures involved in the stress response (Nemeroff and
Owens, 2004; McEwen, 2004; Mayberg et al., 2005; Joels,
2008). We explored the variations in mRNA levels encoding can-
didate genes selected for their implication in mood disorders,
including G protein-coupled receptors (GPCR), transcription
factors, and genes involved in the stress response (Koch et al.,
2002; Calfa et al., 2003; Avissar et al., 2004; de Kloet et al., 2005;
Matuzany-Ruban et al., 2005; Schreiber and Avissar, 2007; Perlis
et al., 2007; Holsboer, 2008). Among these genes, only three dis-
played a change in mRNA levels in the chronic corticosterone
group that was reversed by fluoxetine treatment. Furthermore,
this bidirectional change was only observed in the hypothalamus.
Interestingly, all three genes are involved in GPCR signaling (b-ar-
restin 1 and 2 and Gia2; Figures 4 and S6). The present data are
consistent with previous findings in animal and human studies
showing decreases in b-arrestin 1 and 2 or Gia2 in depression
or after stress, and reversal of these changes by various antide-
pressant treatments (Dwivedi et al., 2002; Avissar et al., 2004).
Interestingly, CRF1 receptor, a potential target for the treatment490 Neuron 62, 479–493, May 28, 2009 ª2009 Elsevier Inc.of depression/anxiety and other stress-related disorders, has
been shown to recruit b-arrestin 2 (Oakley et al., 2007). Moreover,
Beaulieu et al. (2008) have recently shown that lithium, a drug
used in the management of mood disorders, exerts some of its
biochemical and behavioral effects via a b-arrestin signaling
complex.
b-arrestin 2 Is Required for Both Neurogenesis-
Dependent and -Independent Effects of Fluoxetine
Interestingly, the effects of chronic corticosterone on behavior
were similar to those of the b-arrestin 2 ablation (Figure 5,
Figures S7E–S7H). Given that chronic corticosterone treatment
decreases b-arrestin levels (particularly in the hypothalamus), it
is possible that b-arrestin 2 (Figure 5), at least in part, is respon-
sible for mediating the effects of corticosterone on behavior.
Furthermore, b-arrestin 2 knockout mice displayed a reduced
response to fluoxetine in the OF and NSF paradigms. This
suggests that b-arrestin 2 modulates the behavioral response
to fluoxetine in both neurogenesis-independent and -dependent
tasks.
To further understand how b-arrestin 2 may regulate multiple
effects of chronic corticosterone and fluoxetine treatments on
behavior, future work will require the usage of tissue-specific
knockouts. Classical b-arrestin functions include desensitization
of GPCRs (Gainetdinov et al., 2004), so it is possible that
b-arrestin 2 may be important for desensitization of 5-HT1A
receptors in the Raphe Nucleus, a process that has been hypoth-
esized as necessary for the effects of fluoxetine (Artigas et al.,
1996). However, our preliminary results suggest that 5-HT1A
autoreceptor desensitization in response to chronic fluoxetine
is normal in b-arrestin 2 knockout mice. Alternatively, other cell
signaling functions of b-arrestins have also been uncovered
(Pierce and Lefkowitz, 2001; Beaulieu et al., 2005, 2008; Lefko-
witz et al., 2006), and some of lithium’s behavioral effects appear
to be mediated by a b-arrestin 2/Akt/Gsk3b signaling pathway.
When compared to corticosterone-treated mice, the
b-arrestin-2-deficient mice display many similar phenotypes
(Table 1). However, while the corticosterone-treated mice
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Neurogenesis and the Antidepressant Responserespond to fluoxetine, in most behavioral readouts the b-arrestin-
2-deficient mice do not, suggesting that b-arrestin 2 may be an
essential mediator of the fluoxetine-induced reversal of an
anxious/depressed state.
Conclusion
We have developed an anxiety/depression-like model based on
elevation of glucocorticoid levels that offers an easy and reliable
alternative to existing models such as the various chronic stress
paradigms. It is also a model that allows the simultaneous study
of multiple effects of antidepressant treatment in the same animal,
some of which are neurogenesis-dependent while others are not.
The big unanswered question is which of these behavioral,
cellular, and molecular readouts are most relevant to antidepres-
sant action in human. In other words, would a compound that
produces just neurogenesis-dependent effects or just some of
the neurogenesis-independent effects reported here be as effec-
tive as SSRIs or tricyclics? To begin to answer this question, we
are currently testing in this paradigm a series of compounds that
may stimulate neurogenesis more directly than SSRIs, such as
agomelatine, or compounds that target more directly the HPA
axis, such as CRF1 antagonists. Ultimately, the success of these
new compounds in the clinic will inform us about the predictive
value of the biomarkers that we have indentified in this report.
EXPERIMENTAL PROCEDURES
Additional experimental procedures are available online in Supplemental Data.
Subjects
Adult male C57BL/6Ntac mice were purchased from Taconic Farms (German-
town, NY, USA; Lille Skensved, Denmark). Male heterozygous b-arrestin 2+/
and heterozygous female mutant b-arrestin 2+/ mice (age 4–6 months,
25–30 g body weight) were bred on a mixed S129/Sv x C57BL/6 genetic back-
ground at Columbia University (New York, NY). Resulting pups were genotyped
by polymerase chain reaction (Beaulieu et al., 2008). All corticosterone-treated
mice were 7–8 weeks old and weighed 23–35 g at the beginning of the treat-
ment, were maintained on a 12L:12D schedule, and were housed five per
cage. b-arrestin 2 mice began receiving fluoxetine at 3 months. Food and water
were provided ad libitum. Behavioral testing occurred during the light phase for
the OF, NSF, FST, and splash test. All testing was conducted in compliance
with the NIH laboratory animal care guidelines and with protocols approved
by the Institutional Animal Care and Use Committee (Council directive # 87-
848, October 19, 1987, Ministe`re de l’Agriculture et de la Foreˆt, Service Ve´te´r-
inaire de la Sante´ et de la Protection Animale, permissions # 92-256 to D.J.D.).
Drugs
Corticosterone (from Sigma, St. Louis, MO) was dissolved in vehicle (0.45%,
Sigma, St Louis, MO). Imipramine hydrochloride (40 mg/kg per day) and fluox-
etine hydrochloride (18 mg/kg per day) were purchased from Sigma (St. Louis,
MO, USA) and Anawa Trading (Zurich, Switzerland), respectively. Reboxetine
hydrochloride (Lundbeck Inc.) (20 mg/kg per day) was also used for behavior
testing. Corticosterone (7 ug/ml or 35 ug/ml, equivalent to 1 and 5 mg/kg/day)
was delivered alone or in presence of antidepressant in opaque bottles to
protect it from light, available ad libitum in the drinking water. Corticosterone
treatment did not modify levels of antidepressant in the brain (data not shown).
Control mice received b-CD. For b-arrestin-2 mice, fluoxetine was delivered by
a standard gavage protocol (18 mg/kg/day).
Behavioral Testing
Open Field
This test was performed as described previously (Dulawa et al., 2004). Briefly,
motor activity was quantified in four Plexiglas open field boxes 43 x 43 cm2(MED Associates, Georgia, VT). Two sets of 16 pulse-modulated infrared pho-
tobeams on opposite walls 2.5 cm apart recorded x-y ambulatory movements.
Activity chambers were computer interfaced for data sampling at 100 ms reso-
lution. The computer defined grid lines dividing center and surround regions,
with the center square consisting of four lines 11 cm from the wall.
Novelty Suppressed Feeding
NSF is a conflict test that elicits competing motivations: the drive to eat and the
fear of venturing into the center of the brightly lit arena. The NSF test was
carried out during a 10 min period as previously described (Santarelli et al.,
2003; David et al., 2007). For more detail please see Supplemental Data.
Forced Swim Test
A modified FST procedure consisting of an increase in water depth was used
to enhance sensitivity for detecting putative antidepressant activity of drugs
(Porsolt et al., 1977; Dulawa et al., 2004). Mice were placed into plastic buckets
(19 cm diameter, 23 cm deep, filled with 23C–25C water) and videotaped for
the entire session. As described previously by Porsolt et al. (1977), only the last
4 min were scored for mobility duration.
Data Analysis and Statistics
Results from data analyses were expressed as mean ± SEM. Data were
analyzed using StatView 5.0 software (SAS Institute, Cary, NC). For all experi-
ments, one-way, two-way, or three-way ANOVAs with repeated-measure were
applied to the data as appropriate. Significant main effects and/or interactions
were followed by Fisher’s PLSD post hoc analysis, unpaired t tests, or New-
man-Keuls as appropriate. In the NSF test, we used the Kaplan-Meier survival
analysis due to the lack of normal distribution of the data. Animals that did not
eat during the 10 min testing period were censored. Mantel-Cox log-rank test
was used to evaluate differences between experimental groups.
SUPPLEMENTAL DATA
The supplemental data for this article include supplemental experimental
procedures, four tables, and eight figures and can be found at http://www.
neuron.org/supplemental/S0896-6273(09)00298-0.
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